We've noticed that you're using an ad blocker

Our content is brought to you free of charge because of the support of our advertisers. To continue enjoying our content, please turn off your ad blocker.

It's off now Dismiss How do I disable my ad blocker?
❌

How to disable your ad blocker for our site:

Adblock / Adblock Plus
  • Click on the AdBlock / AdBlock Plus icon on the top right of your browser.
  • Click “Don’t run on pages on this domain.” OR “Enabled on this site.”
  • Close this help box and click "It's off now".
Firefox Tracking Prevention
  • If you are Private Browsing in Firefox, "Tracking Protection" may casue the adblock notice to show. It can be temporarily disabled by clicking the "shield" icon in the address bar.
  • Close this help box and click "It's off now".
Ghostery
  • Click the Ghostery icon on your browser.
  • In Ghostery versions < 6.0 click “Whitelist site.” in version 6.0 click “Trust site.”
  • Close this help box and click "It's off now".
uBlock / uBlock Origin
  • Click the uBlock / uBlock Origin icon on your browser.
  • Click the “power” button in the menu that appears to whitelist the current website
  • Close this help box and click "It's off now".
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

Modern Medicine Network
  • Login
  • Register
Skip to main content
Modern Medicine Network
  • Login
  • Register
Menu
User
Home
  • ONCOLOGY
  • News
  • Blogs
  • Topics
  • Hematology
  • Image IQ
  • Podcasts
  • Videos
  • Slideshows
  • Conferences

SUBSCRIBE: Print / eNewsletter

Chemo-Related Febrile Neutropenia Rates Higher in Elderly

Nov 1, 2002
Volume: 
11
Issue: 
11

BOSTON—Researchers
from the Awareness of Neutropenia in Chemotherapy (ANC) Study Group report that
older cancer patients are at greater risk of death due to chemotherapy-related
febrile neutropenia. They recommend that the elderly receive prophylactic
colony-stimulating factors (CSFs) as adjuncts to CHOP and CHOP-like
chemotherapy regimens.

The group’s findings, presented at the third meeting of the
International Society of Geriatric Oncology (SIOG), were based on two studies:
a retrospective analysis of more than 55,000 episodes of febrile neutropenia
(abstract P-25) and a review of 11 randomized CHOP trials from which data could
be extracted for older patients (abstract O-7B-02).

The ANC Study Group receives support from Amgen Inc. of
Thousand Oaks, California, which manufactures the CSFs filgrastim (Neupogen)
and pegfilgrastim (Neulasta).

The first study reviewed discharge information for adult,
nontransplant patients admitted with febrile neutropenia from 1995 to 2000 at
115 teaching hospitals in the University HealthSystem Consortium (UHC)
database. Jeffrey Crawford, MD, director of clinical research, Duke University
Comprehensive Cancer Center, and his colleagues reported that patients age 65
and older accounted for 27% of admissions for febrile neutropenia but 36% of
inpatient deaths.

The researchers found 55,276 episodes of febrile neutropenia
in 41,779 patients during this 6-year period. More than 14,000 episodes
occurred in patients age 65 or older.

The large number surprised the investigators, Dr. Crawford
said. "I think this has to do with the lack of appreciation of the magnitude of
this problem," he told ONI, suggesting that many oncologists don’t
recognize how frequently neutropenia occurs or how much it interferes with
treatment.

"Unfortunately, our strategy for altering chemotherapy doses
or adding CSF support is more reactive than proactive," he added. "The data
speak to that. We’re getting thousands of admissions per year in these 115
institutions of patients over 65. We’re clearly not identifying these patients
well enough prospectively."

Pages

  • 1
  • 2
  • 3
  • next ›
  • last »

Resource Topics rightRail

  • Resource Topics
  • Partner Content
Breast Cancer
Lung Cancer
Prostate Cancer
Colorectal Cancer
Melanoma
Cutaneous T-Cell Lymphomas: Mycosis Fungoides and Sézary Syndrome
3 Keys to Success in the Oncology Care Model

Current Issue

Oncology Vol 32 No 4
Apr 15, 2018 Vol 32 No 4
Digital Edition
Subscribe
Connect with Us
  • Twitter
  • Facebook
  • LinkedIn
  • RSS
Modern Medicine Network
  • Home
  • About Us
  • Advertise
  • Advertiser Terms
  • Privacy statement
  • Terms & Conditions
  • Editorial & Advertising Policy
  • Editorial Board
  • Contact Us
Modern Medicine Network
© UBM 2018, All rights reserved.
Reproduction in whole or in part is prohibited.